Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.
colorectal cancer
primary tumor size
prognostic factors
survival outcomes
therapy response determinants
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
06
2021
accepted:
27
10
2021
entrez:
27
12
2021
pubmed:
28
12
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Pathologic staging is crucial in colorectal cancer (CRC). Unlike the majority of solid tumors, the current staging model does not use tumor size as a criterion. We evaluated the predictive and prognostic impact of primary tumor size on all stages of CRC. Using the National Cancer Database (NCDB), we conducted an analysis of CRC patients diagnosed between 2010 and 2015 who underwent resection of their primary cancer. Univariate and multivariate analyses were used to identify predictive and prognostic factors, Kaplan-Meier analysis and Cox proportional hazards models for association between tumor size and survival. About 61,000 patients met the inclusion criteria. Median age was 63 years and majority of the tumors were colon primary (82.7%). AJCC stage distribution was: I - 20.1%; II - 32.1%; III - 34.7% and IV - 13.1%. The prognostic impact of tumor size was strongly associated with survival in stage III disease. Compared to patients with tumors <2cm; those with 2-5cm (HR 1.33; 1.19-1.49; p<0.001), 5-10cm (HR 1.51 (1.34-1.70; p<0.001) and >10cm (HR 1.95 (1.65-2.31; p<0.001) had worse survival independent of other variables. Stage II treated without adjuvant chemotherapy had comparable survival outcomes (HR 1.09; 0.97-1.523; p=0.148) with stage III patients who did, while Stage II patients who received adjuvant chemotherapy did much better than both groups (HR 0.76; 0.67-0.86; p<0.001). Stage III patients who did not receive adjuvant chemotherapy had the worst outcomes among the non-metastatic disease subgroups (HR 2.66; 2.48-2.86; p<0.001). Larger tumors were associated with advanced stage, MSI high, non-rectal primary and positive resection margins. Further studies are needed to clarify the role of tumor size in prognostic staging models, and how to incorporate it into therapy decisions.
Sections du résumé
BACKGROUND
BACKGROUND
Pathologic staging is crucial in colorectal cancer (CRC). Unlike the majority of solid tumors, the current staging model does not use tumor size as a criterion. We evaluated the predictive and prognostic impact of primary tumor size on all stages of CRC.
METHODS
METHODS
Using the National Cancer Database (NCDB), we conducted an analysis of CRC patients diagnosed between 2010 and 2015 who underwent resection of their primary cancer. Univariate and multivariate analyses were used to identify predictive and prognostic factors, Kaplan-Meier analysis and Cox proportional hazards models for association between tumor size and survival.
RESULTS
RESULTS
About 61,000 patients met the inclusion criteria. Median age was 63 years and majority of the tumors were colon primary (82.7%). AJCC stage distribution was: I - 20.1%; II - 32.1%; III - 34.7% and IV - 13.1%. The prognostic impact of tumor size was strongly associated with survival in stage III disease. Compared to patients with tumors <2cm; those with 2-5cm (HR 1.33; 1.19-1.49; p<0.001), 5-10cm (HR 1.51 (1.34-1.70; p<0.001) and >10cm (HR 1.95 (1.65-2.31; p<0.001) had worse survival independent of other variables. Stage II treated without adjuvant chemotherapy had comparable survival outcomes (HR 1.09; 0.97-1.523; p=0.148) with stage III patients who did, while Stage II patients who received adjuvant chemotherapy did much better than both groups (HR 0.76; 0.67-0.86; p<0.001). Stage III patients who did not receive adjuvant chemotherapy had the worst outcomes among the non-metastatic disease subgroups (HR 2.66; 2.48-2.86; p<0.001). Larger tumors were associated with advanced stage, MSI high, non-rectal primary and positive resection margins.
CONCLUSIONS
CONCLUSIONS
Further studies are needed to clarify the role of tumor size in prognostic staging models, and how to incorporate it into therapy decisions.
Identifiants
pubmed: 34956863
doi: 10.3389/fonc.2021.728076
pmc: PMC8695445
doi:
Types de publication
Journal Article
Langues
eng
Pagination
728076Informations de copyright
Copyright © 2021 Alese, Zhou, Jiang, Zakka, Huang, Okoli, Shaib, Akce, Diab, Wu and El-Rayes.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Colorectal Dis. 2021 Jan;23(1):192-199
pubmed: 32976668
Surgery. 2021 May;169(5):1116-1123
pubmed: 33334582
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
BMC Med. 2020 Jun 26;18(1):172
pubmed: 32586325
Cancer. 2000 Apr 1;88(7):1739-57
pubmed: 10738234
J Surg Oncol. 2021 Feb;123(2):596-605
pubmed: 33125756
Ann Surg Oncol. 2017 Feb;24(2):311-318
pubmed: 27766558
World J Gastroenterol. 2016 Aug 7;22(29):6726-35
pubmed: 27547015
Am J Gastroenterol. 1999 Oct;94(10):3039-45
pubmed: 10520866
F1000Res. 2018 Dec 19;7:1955
pubmed: 31231506
J Gastroenterol Hepatol. 2007 Dec;22(12):2288-91
pubmed: 18031394
Cancer. 2001 Nov 15;92(10):2547-54
pubmed: 11745188
Br J Cancer. 2005 Aug 22;93(4):399-405
pubmed: 16106247
Cancer. 2014 Sep 15;120(18):2893-901
pubmed: 24894740
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Cancer. 2016 Nov 15;122(21):3277-3287
pubmed: 27417445
Cancer Epidemiol. 2019 Dec;63:101618
pubmed: 31600666
Int J Colorectal Dis. 2015 Jan;30(1):131-7
pubmed: 25392257
Am J Gastroenterol. 2005 Mar;100(3):515-23; discussion 514
pubmed: 15743345
Medicine (Baltimore). 2016 Feb;95(6):e2711
pubmed: 26871810
Clin Colorectal Cancer. 2018 Sep;17(3):e513-e518
pubmed: 29661621
Med Oncol. 2014 Dec;31(12):305
pubmed: 25355641
Oncotarget. 2018 Feb 13;9(17):13834-13847
pubmed: 29568398
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Surg Res. 2017 Jul;215:12-20
pubmed: 28688636
Am J Surg. 2015 Mar;209(3):570-4
pubmed: 25601557
Int J Colorectal Dis. 2018 Oct;33(10):1349-1357
pubmed: 29938362
Mayo Clin Proc. 2014 Feb;89(2):216-24
pubmed: 24393412
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Oncologist. 2020 Mar;25(3):244-251
pubmed: 32162825
Am J Clin Oncol. 2011 Feb;34(1):43-9
pubmed: 20101166
Front Oncol. 2021 Mar 30;11:592351
pubmed: 33859934